First-in-human, open-label dose-escalation and dose-expansion study of the safety, pharmacokinetics, and antitumor effects of an oral ALK inhibitor ASP3026 in patients with advance...

por Li, Tianhong, LoRusso, Patricia, Maitland, Michael L., Ou, Sai-Hong Ignatius, Bahceci, Erkut, Ball, Howard A., Park, Jung Wook, Yuen, Geoffrey, Tolcher, Anthony
Publicado 2016